Market research
6C1.F CytomX Therapeutics, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 617M
- P/E ratio
- Not available
- Analyst target
- 13.14
- Dividend yield
- Not available
- Beta
- 2.14
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US23284F1057
- Market cap
- 617M
- P/E ratio
- Not available
- Analyst target
- 13.14
- Dividend yield
- Not available
- Beta
- 2.14
About
About CytomX Therapeutics, Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 6C1.F discussion.
5 years, 5 months ago
CytomX Therapeutics, Inc is currently in a long term downtrend where the price is trading 20.9% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.5.
CytomX Therapeutics, Inc's total revenue rose by 97.8% to $16M since the same quarter in the previous year.
Its net income has increased by 58.5% to $-15M since the same quarter in the previous year.
Finally, its free cash flow grew by 40.8% to $-18M since the same quarter in the previous year.
Based on the above factors, CytomX Therapeutics, Inc gets an overall score of 4/5.